A 5-year nationwide prospective study in Sweden during 1995-1999 identified 881 definite episodes of infective endocarditis. Definite enterococcal endocarditis was diagnosed in 93 episodes (11%), the largest series of enterococcal endocarditis so far presented. Mortality during treatment was 16%, the relapse rate was 3%, and clinical cure was achieved in the remaining 81% of the episodes. Clinical cure was achieved with a median duration of cell wall-active antimicrobial therapy of 42 days combined with an aminoglycoside (median treatment time, 15 days). International guidelines generally recommend a 4-6-week combined synergistic treatment course with a cell wall-active antibiotic and an aminoglycoside. Treatment regimens in Sweden often include a shortened aminoglycoside treatment course in order to minimize adverse effects in older patients. Fatal outcome seemed not to be due to the shortened aminoglycoside therapy course. In many enterococcal endocarditis episodes, duration of aminoglycoside therapy could probably be shortened to 2-3 weeks.
Treatment of infective endocarditis (IE) is associated with problems for the doctors, but also for the patients. Doctors must decide what antibiotic to use for the infections, but unfortunately, the choice is mainly based on empiric grounds. The patients often have to realize that a longer period of intravenous treatment than they expected is necessary and that side effects during a long treatment period are common. Shorter treatment without loss of effectiveness is desired. It has, however, been shown that uncomplicated IE caused by viridans streptococci can be cured with therapy that lasts only 2 weeks. For other common bacteria, such as enterococci, most recommendations still advise combined treatment with penicillin and an aminoglycoside for as long as 4-6 weeks. One clear drawback of such treatment is the toxicity of aminoglycosides, which grows in importance when treating older patients who are infected with enterococcal endocarditis. Patients with enterococcal endocarditis are now 70-80 years old-perhaps older in Sweden than in most other countries, and certainly older than in previous years. We have studied the possibilities of shortening treatment of enterococcal endocarditis by analyzing cases from an ongoing national registry of IE in Sweden.
PATIENTS AND METHODS
In 1995, a national registry of IE started in Sweden, organized by the Swedish Society for Infectious Diseases. All 30 departments of infectious diseases in hospitals from all parts of the country have participated in registry since its inception. One aim of the registry was to create a consistent diagnostic and therapeutic approach to patients with fever without certain non-cardiac origin. In Sweden, there are no socioeconomic hindrances to admitting patients with fever and or to performing rapid diagnostic procedures. The 30 infectious disease departments have regional responsibility for care of patients with severe infections, and therefore, a majority of IE cases would be registered. During the 5-year period 1995-1999, 1127 cases of IE were reported.
All cases were reported on a standardized questionnaire at the time of discharge, which included information of the patient's age, sex, predisposing factors, history of heart disease, prosthetic valve, and current episode of IE (hospital duration, delay to treatment, location of IE, clinical signs and symptoms, blood culture results, echocardiographic findings, antibiotic and surgical treatment, and final outcome). A second questionnaire was sent after follow-up (mean, 3 months after treatment), which collected data such as reports of death after treatment, relapse, reinfection, or sequelae. A third postoperative questionnaire was sent by 9 departments of cardiothoracic surgery, who also participated in the study.
Data from the returned questionnaires were entered into a computerized database. Each reported episode of IE was categorized by the coordinating investigators according to the Duke diagnostic criteria of IE [1] . Only episodes that fulfilled the Duke criteria of definite endocarditis were included in further analyses.
Isolates of enterococci were identified and speciated according to standard microbiologic methods in the participating centers. In order to identify enterococci, an ID-32 Strep API test is usually performed. Enterococci, with exception of Enterococcus saccharolyticus, are always positive in the included PYR test (hydrolysis of l-pyrrolidyl-b-napthylamine to b-napthylamine). Enterococcus faecalis and Enterococcus faecium can be separated by culturing them on an arabinose plate. E. faecalis is arabinose negative (99%), whereas E. faecium is arabinose positive (95%-97%), as are Enterococcus gallinarum and Enterococcus casseliflavus. Resistant and susceptible strains were defined according to the species-related MIC breakpoints of the Swedish Reference Group for Antibiotics [2] .
Antibiotic treatment was provided according to local treatment recommendations. "b-lactam antimicrobials" are here defined as b-lactam antibiotics with routinely bacteriostatic or bactericidal activity against enterococci (i.e., penicillin G, ampicillin, piperacillin, imipenem-cilastatin). Cell wall-active agents include the b-lactams mentioned above as well as the glycopeptides vancomycin or teicoplanin. Dosing regimens in general have been penicillin G or ampicillin 12 g daily to patients with normal renal function. Vancomycin trough and peak serum levels sought during therapy were !15 mg/L and 30-50 mg/L, respectively. Gentamicin, tobramycin, or netilmicin were in general given in a 3 mg/kg per day schedule to patients with normal renal function. Serum concentrations were followed with estimated trough and peak levels of !2 mg/L and у4 mg/ L, respectively. Once-daily administration of aminoglycosides to patients with normal renal function was not attempted. "Clinical cure" was defined as survival and no relapse during the follow-up period. "Mortality during treatment" was defined as all deaths during parenteral antibiotic therapy, including 1 month after treatment. "Relapse" was defined as a new event of IE by the same species regardless of the time interval between the episodes. "Acute surgery" was defined as cardiac surgery during the period of parenteral antibiotic treatment.
RESULTS
From January 1995 through December 1999, 1127 episodes of IE were reported from Swedish infectious disease departments, and 881 episodes (78%) were classified as definite IE. Enterococcal endocarditis was reported in 114 episodes, and 98 of these were classified as definite IE. In 5 of these 98 definite enterococcal episodes, a double infection was diagnosed (E. faecalis and Staphylococcus aureus in 2 episodes, E. faecalis and Streptococcus agalactiae in 1 episode, E. faecium and Klebsiella oxytoca in 1 episode, and E. faecium and coagulase-negative staphylococci in 1 episode); these were excluded from further analyses. In the remaining 93 definite enterococcal IE episodes, E. faecalis was the causative organism in 78, E. faecium in 5, and E. durans and E. casseliflavus in 1 episode each; the microorganism was not speciated in 8 patients. No vancomycinresistant enterococci were recorded. Enterococci caused 10.5% (yearly range, 7.9%-13.1%) of all reported definite IE episodes.
Demographic and clinical features of all definite IE episodes are presented in table 1. In episodes caused by enterococci as compared with the other IE episodes, risk factors such as prosthetic valves (29% vs. 15%) or a previous endocarditis episode (23% vs. 8%) were more prevalent. The median age of patients was older (74 vs. 63 years), and the patients were mostly men (77%). Aortic valve infections were more common (57% vs. 46%) and isolated right-sided IE less common (5% vs. 13%) in enterococcal IE episodes compared with all IE episodes. In only 5 of the enterococcal episodes were the duration of symptoms 13 months. At least 1 echocardiogram was performed in all patients, and transesophageal echocardiography was performed in 69 patients (74%). A vegetation was visualized in 75% of the patients in whom transesophageal echocardiography were performed and in 63% of the patients in which only a transthoracic echocardiography was performed.
Fatal outcome occurred in 15 patients (16%) on median treatment day 30 (range, 3-64 days). Acute cardiac surgery was performed in 19 patients (20%) on median treatment day 11 (range, 1-51 days). Mortality during treatment for patients subjected to acute surgery or no acute surgery was 5 (26%) of 19 and 10 (14%) of 74, respectively. All but a few surviving patients were followed for 1 month, and reports of follow-up after 1 month (mean, 92 days) were registered for 41 survivors (53%). Follow-up after 1 month (mean, 90 days) was performed in 29 (62%) of 47 patients who had received р21 days of combined aminoglycoside treatment, as compared with 12 (39%) of 31 patients who received longer aminoglycoside treatment. Relapse occurred in 3 patients (7%), reinfection in 2 (5%), and death during the follow-up period in 2 (5%) of the 41 followed surviving patients.
Antibiotic therapy. Clinical cure was achieved in 75 episodes. A cell wall-active antimicrobial therapy was given a median of 42 days, and an aminoglycoside was added a median of 15 days in these episodes (figures 1 and 2). In 7 episodes, no aminoglycoside therapy was provided. Cell wall-active therapy consisted of a b-lactam in 39 patients (52%), vancomycin in 9 (12%), and sequential treatment with these 2 agents in 27 (36%) of the patients who were cured. Ampicillin was given in 58 patients (88%) treated with b-lactams. The median duration of ampicillin treatment was 28 days.
Native valve endocarditis. Native valve endocarditis (NVE) was diagnosed in 66 patients. Median patient age was 73 years (range, 31-87 years), and median time to treatment was 10 days (range, 0-119 days). A cardiac predisposing defect was recognized in 23 patients (35%), previous endocarditis in 13 (20%), and injection drug abuse in 9 (14%) of the patients. Aortic valve was involved in 37 (56%), mitral valve in 27 (41%), and tricuspid valve in 8 (12%) of the episodes. Isolated tricuspid valve endocarditis was diagnosed in 5 (8%) of the episodes. Echocardiography was performed in all patients, and the transesophageal approach was used in 66% of the episodes. A vegetation was defined in 53 (80%) and abscess in 1 (2%) of the episodes.
The patient with an abscess was a 82-year-old man with an aortic NVE with 118 days' delay to treatment. He was treated conservatively with 42 days of b-lactam treatment, which was combined with an aminoglycoside during the first 14 days. He recovered and had no signs of infection clinically or at the time of echocardiographic examination at follow-up 4 months after treatment.
Overall clinical cure was achieved in 54 (82%) of 66 episodes. In episodes with clinical cure a cell wall-active antimicrobial therapy was given median 42 days, and an aminoglycoside was added median 16 days. A b-lactam-most often, ampicillinwas given in 48 episodes; in 17 of these, a b-lactam and vancomycin was given as sequential therapy. Vancomycin was given as the only cell wall-active therapy in 6 episodes. Treatment mortality was 10 (15%) of 66 patients. Two relapses occurred. Acute valvular surgery was performed in 11 patients (17%) on median treatment day 9; clinical cure was achieved in 9 (82%) Figure 2 . Duration of combined aminoglycoside therapy in 75 episodes of enterococcal endocarditis that were cured of 11 of these patients, as compared with 45 (82%) of 55 of the patients not subjected to valvular surgery.
Ten fatal episodes are described in table 2. Patients 1, 2, 4, and 6 died during or shortly after combined synergistic therapy. Patients 3 and 5 died while receiving single-antibiotic therapy. In patient 3, synergistic therapy was given for only 14 days, and the patient died as a result of cardiac failure after 28 days of treatment. In this patient, shortened synergistic bactericidal therapy might have been implicated in the fatal outcome. In patient 5, aminoglycoside therapy was halted because of severe renal insufficiency after 21 days of therapy; the cause of death was anuria and severe sequelae after enterococcal meningitis. Four patients died after antibiotic therapy was halted. Aminoglycoside therapy was given for 38 days to patients 7 and 10 and for a shorter period to patients 8 and 9 (7 and 21 days, respectively). The cause of death in the last 2 episodes could theoretically be attributable to shortened aminoglycoside therapy. In summary, a shortened aminoglycoside therapy could theoretically be implicated in 3 deaths, but this cannot be definitively proven.
Prosthetic valve endocarditis. Prosthetic valve endocarditis was diagnosed in 27 (29%) of 93 patients. Median age was 75 years (range, 41-85 years), and the median time to treatment was 8 days (range, 1-76 days). Clinical cure was achieved in 21 (78%) of 27 episodes. In patients who achieved clinical cure, a cell wall-active antimicrobial therapy was given a median of 42 days, and a synergistic aminoglycoside was added for a median of 15 days. A b-lactam-most often ampicillin-was given in 18 episodes; in 10 of these, a b-lactam and vancomycin were given as sequential therapy. Vancomycin was given as the only cell wall-active therapy in 3 episodes. Five (19%) of 27 patients died. One relapse was noted. Acute valvular surgery was performed in 8 patients (30%) on median treatment day 18; clinical cure was achieved in 6 (75%) of 8 of these patients as compared with 15 (79%) of 19 of the patients not subjected to valvular surgery.
Echocardiography was performed in all patients, and the transesophageal approach was used in 25 episodes. A vegetation was documented in 14 (52%), abscess in 4 (15%), and a new paravalvular insufficiency in 9 (33%) of the 27 episodes. Three of 4 patients with abscesses underwent surgical valve replacement as part of treatment, and they experienced clinical cure. The remaining patient with an abscess was treated conservatively with an aminoglycoside for 31 days and a total antibiotic treatment duration of 37 days; this patient experienced clinical recovery. At follow-up 3 months after treatment, an aortic paravalvular insufficiency was the only remaining sequela.
The 5 fatal episodes are described in table 3. In fatal episodes, combined therapy was provided during the whole treatment period in 3 episodes, but was halted because of severe renal insufficiency after 17 days of therapy in patient 4, and only given for 8 out of 28 days to patient 3. The last patient died as a result of cardiac failure after 28 days of treatment, and this is the only patient in whom shortened combined therapy theoretically might have been implicated in the fatal outcome.
Relapse. Three (3%) of 93 patients experienced relapse. One 41-year-old woman had, 39 months earlier, been treated for S. aureus endocarditis with a spondylitis; she now presented with aortic E. faecalis NVE, with a time to treatment of 15 days. She developed heart failure and received a new aortic prosthesis on treatment day 5. She received 34 days of combined treatment with ampicillin and an aminoglycoside. Twenty-two days after treatment, E. faecalis reappeared in blood cultures, and she received another 34 days of combined treatment; an exchange of aortic prosthesis was performed 15 days after treatment. She died as a result of cerebral embolism 13 days postoperatively.
An 87-year-old man had, 31 months previously, been treated for a Streptococcus mutans endocarditis and had now an E. faecalis mitral NVE with only 3 days of clinical symptoms. He received 28 days of ampicillin treatment, and an aminoglycoside was provided for only 7 days. Clinical symptoms of relapse started 6 days after treatment. He then received 28 days of ampicillin and aminoglycoside therapy, followed by teicoplanin for 14 days. He recovered, but lifelong amoxicillin prophylaxis is planned. In this patient, clinical failure with relapse could probably be attributed to the short duration of combined aminoglycoside therapy.
The third relapse was that of a 79-year-old man with an early E. faecium aortic prosthetic valve endocarditis with 60 days' delay to treatment. He was treated with vancomycin for 42 days; this was combined with an aminoglycoside for 27 days, but a relapse with E. faecium in blood cultures was diagnosed 69 days after treatment, and the patient died.
No aminoglycoside therapy. Seven patients never received any combined synergistic aminoglycoside therapy, and they all recovered from the IE episodes. Enterococcal species were E. faecalis in 5 episodes, E. faecium in 1 episode, and not further speciated in 1 episode. None of these patients required acute surgery. Median age was 79 years (range, 56-83 years); the aortic valve was involved in 6 patients and the mitral valve in 2. Total treatment duration was a median of 42 days (range, 42-90 days). Vancomycin was given as single agent in 4 patients, ampicillin in 2 patients, and a combination of these agents in 2 patients. They were followed for a median 50 of days (range, 39-79 days) after treatment without any signs of relapse.
Long delay to treatment. Five patients had clinical symptoms of IE during у3 months (mean, 104 days; range, 90-119 days) before adequate therapy was installed. All had native aortic valve infection; in one patient, this was combined with a mitral valve infection. All patients had vegetations. Clinical peripheral embolism was noted in 4 episodes. Two patients underwent acute prosthesis exchange on treatment days 2 and 33, respectively. The only fatal episode was in a patient who underwent surgery on treatment day 33 when an abscess was diagnosed. He died as a result of paravalvular leakage, cardiac failure, and cerebral embolism. He received a combined aminoglycoside therapy for 38 days. No episode with relapse was noted. Three of the 4 surviving patients were followed for a mean of 95 days (range, 49-142 days); 1 patient was lost to follow-up. The patients with clinical cure were treated for a mean of 37 days (range, 32-42 days) with a cell wall-active antimicrobial, and an aminoglycoside was added for a mean of 18 days (range, 14-22 days) in 3 of 4 episodes. In the remaining episode, no aminoglycoside therapy was provided.
DISCUSSION
Enterococcal endocarditis has always been regarded as a difficult-to-cure infection, even before emerging resistance to aminoglycosides, b-lactams, and glycopeptides was recognized. Un- acceptable rates of failures were observed when penicillin alone was used as treatment. The enterococci are inherently more resistant to b-lactam antibiotics and are typically more tolerant to the bactericidal activity of these and other antimicrobial agents that act at the level of cell wall synthesis. With the introduction of streptomycin, Hunter [3] reported in 1947 of the empirical use of this drug to treat 5 patients with enterococcal endocarditis. The only patient who responded had received concomitant therapy with penicillin G. Bactericidal synergism between penicillin G and streptomycin against enterococci could be demonstrated in vitro by time-kill techniques in 1950 [4] . The relatively few published series of enterococcal endocarditis treated with a combination of a cell wall-active antibiotic and an aminoglycoside have yielded cure rates of 50%-88% with a mean combined antibiotic treatment duration of 4.0-6 weeks (table 4). In retrospect, it is important to note that not all infections treated with penicillin alone failed to respond to therapy. In a 1954 Mayo Clinic review, 7 (39%) of 18 patients treated with penicillin alone were cured; of those who received 16 million units (3.6 g) per day, half were cured [5] .
Enterococci seem to have strain variability, with some isolates readily undergoing killing and cell lysis on exposure to penicillins; others are quite tolerant [11] [12] [13] . Tolerance of enterococci might very well be an acquired trait, as has been observed in antibiotic-naïve E. faecalis isolates collected in the Solomon Islands in the early 1970s [14] . Initially, they were readily killed by penicillin at concentrations near the MIC, but after exposure to pulses of penicillin, tolerance soon was achieved [14] . Continued exposure to a fixed concentration of penicillin did not, however, induce tolerance [15] .
For E. faecalis, MIC 90 values of 1 mg/L for ampicillin and 2 mg/L for penicillin G and vancomycin have been reported. Ampicillin in combination with an aminoglycoside is considered as first-line treatment option in episodes with E. faecalis endocarditis. E. faecium strains are typically resistant to b-lactams, whereas the MIC 90 for vancomycin is still 2 mg/L [14] . For teicoplanin, the lowest MIC 90 to E. faecalis and E. faecium (0.5 mg/L) of all tested antibiotics has been reported, but the clinical experience of endocarditis therapy with teicoplanin is still limited.
The American Heart Association recommends a 4-week combined treatment course for patients with symptoms of !3 months' duration and a 6-week treatment course for patients with longer symptom duration, on the basis of studies by Wilson et al. [9, 15] . In Great Britain, published guidelines recommend 4 weeks of combined treatment in all aminoglycosidesensitive enterococcal endocarditis episodes [16] . The duration of the aminoglycoside treatment has not been studied, and the same combination treatment has usually been used throughout the treatment period. Emerging resistance to b-lactams, glycopeptides, and also aminoglycosides has complicated therapeutic options in enterococcal endocarditis, although this is not the topic of this report.
One drawback of therapy of enterococcal endocarditis is the long treatment period with aminoglycosides in an elderly population. In Sweden, gentamicin, tobramycin, or netilmicin are the aminoglycosides used most often in clinical practice, and streptomycin is not available for general use. To avoid the wellknown adverse events of nephrotoxicity and ototoxicity, serum concentrations of aminoglycosides have to be determined. A lower dose of gentamicin, tobramycin, or netilmicin of 3 mg/ kg per day in patients with normal renal function is enough to achieve synergism while limiting renal adverse effects [9] . Despite careful dosage, renal function is often impaired, necessitating the withdrawal of the aminoglycoside. In Sweden, a shortened aminoglycoside treatment course in order to avoid nephrotoxic or ototoxic adverse effects often has been used in clinical practice without apparent negative consequences.
During the 5-year period of this study, 93 episodes of definite enterococcal IE were registered, which is the largest series of enterococcal endocarditis episodes reported to date. Enterococci constituted 11% of all episodes, well in accordance with the frequency of 5%-15% in previous series [17, 18] . This study period was only 5 years, which favored standardized treatment regimens with only minor changes over time. 
